OncLive Staff

Vepdegestrant boosts PFS in select ESR1-mutated breast cancer, maintenance OSE2101 combination provides survival benefit in PDAC, and more from OncLive.

The top 5 OncLive videos of the week cover insights in TGCT, NSCLC, TNBC, AML, and MDS.

Tislelizumab regimen wins approval in ESCC, perioperative durvalumab plus chemotherapy boosts EFS in gastric/GEJ cancer, and more from OncLive this week.

Co-hosts Kristie L. Kahl and Andrew Svonavec highlight the many advantages to attending the 42nd Annual Miami Breast Cancer Conference, with some additional tidbits to round out the main event.

The top 5 videos of the week cover insights in ovarian cancer, NSCLC, CSCC, follicular lymphoma, and CLL.

A recap of the top data presented at the 2025 Gastrointestinal Cancers Symposium.

Nivolumab plus ipilimumab produced a statistically significant and clinically meaningful OS benefit vs SOC in systemic therapy–naive unresectable HCC.

This week’s top 5 includes a snapshot of FDA approvals from December, an exclusive roundup of critical NCCN guideline updates from 2024, and more.

The FDA awards accelerated approval to encorafenib regimen in BRAF V600E+ CRC, ensartinib wins approval in ALK+ non–small cell lung cancer, and more.

Fixed-duration acalabrutinib combination improves PFS in CLL, imlunestrant ± abemaciclib boosts PFS in ESR1-mutated ER+ breast cancer, and more.

OncLive co-hosts Kristie L. Kahl and Andrew Svonavec highlight abstracts for medical oncologists to look out for at the upcoming ASH Annual Meeting in San Diego, with some additional tidbits to round out the main event.

Belantamab mafodotin is under FDA review in multiple myeloma, and Suneel Kamath, MD, highlights pancreatic cancer awareness month.

Zanidatamab scores approval for HER2+ biliary tract cancer, Versamune HPV is under exploration in HPV16+ head and neck squamous cell carcinoma, and more.

New datopotamab deruxtecan BLA in NSCLC filed to FDA, radiopharmaceutical meets rPFS end point in PSMA+ prostate cancer, and more.

Obe-cel wins FDA approval in relapsed/refractory B-cell ALL, FDA approval is sought for sunvozertinib in EGFR exon 20–positive NSCLC, and more.

OncLive co-hosts Kristie L. Kahl and Andrew Svonavec talk to program co-chair Benjamin P. Levy, MD, to highlight what to expect in the latest oncology developments from the 42nd Annual Chemotherapy Foundation Symposium to be held in New York City.

Asciminib gets FDA accelerated approval for chronic-phase CML, RMC-9805 shows activity in KRAS G12D+ pancreatic cancer, and more from OncLive this week.

The FDA has expanded the approval of methotrexate to include use in pediatric patients with acute lymphoblastic leukemia.

FDA accepts rivoceranib/camrelizumab NDA for review in HCC, acalabrutinib triplet yields responses in untreated mantle cell lymphoma, and more from OncLive this week.

Inavolisib triplet wins FDA approval in PIK3CA+ breast cancer, perioperative pembrolizumab improves EFS in head and neck cancer, and more from OncLive this week.

Perioperative nivolumab receives FDA approval for resectable NSCLC, acalabrutinib sNDA gets priority review for MCL, and more from OncLive this week.

The FDA’s ODAC votes against the risk:benefit profile of frontline PD-1 inhibitors in select tumor types, osimertinib gains approval for select NSCLC, and more this week from OncLive.

Adjuvant ribociclib receives FDA approval for HR+ breast cancer, AMG 193 elicits responses in MTAP-deleted solid tumors, and more this week from OncLive.

OncLive co-hosts Kristie L. Kahl and Andrew Svonavec highlight abstracts for medical oncologists to look out for at the upcoming ESMO Congress in Barcelona, with some additional tidbits to round out the main event.

This list features a snapshot of key August FDA oncology decisions, efforts to integrate health equity into guideline development, and more.

Mirdametinib NDA gets priority review in NF1-associated plexiform neurofibromas, experts explore social media's evolving role in cancer care, and more.

A frontline doublet receives FDA approval in EGFR+ NSCLC, a CRL is issued to linvoseltamab in multiple myeloma, and more this week from OncLive.

OncLive honors 15 oncology leaders with the 2024 Giants of Cancer Care awards for their innovations in improving patient outcomes.

OncLive co-hosts Kristie L. Kahl and Andrew Svonavec highlight abstracts to look out for at the upcoming ASCO Annual Meeting in Chicago, with some additional tidbits to round out the main event.

Prateek Gulhati, MD, PhD, delivers takeaways from his presentation at the 2022 Annual Oncology Clinical Practice and Research Summit and key trials in pancreatic cancer that have moved the field forward.